Scarica l'app Stockscreener
5.14
0.98%
0.05
Dopo l'orario di chiusura:
5.14
Precedente Chiudi:
$5.09
Aprire:
$5.12
Volume 24 ore:
708.31K
Relative Volume:
0.88
Capitalizzazione di mercato:
$410.20M
Reddito:
$116.30M
Utile/perdita netta:
$17.73M
Rapporto P/E:
24.48
EPS:
0.21
Flusso di cassa netto:
$20.88M
1 W Prestazione:
-1.15%
1M Prestazione:
-20.92%
6M Prestazione:
-49.21%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.03
$5.236
Intervallo di 1 settimana:
$4.925
$5.31
Portata 52W:
$4.925
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
5.14 | 406.21M | 116.30M | 17.73M | 20.88M | 0.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Potential Upside of Over 210% Draws Investor Attention - DirectorsTalk Interviews
Is Niagen Bioscience Inc. a cyclical or defensive stockEarnings Beat & Real-Time Buy Signal Alerts - mfd.ru
How is Niagen Bioscience Inc. managing supply chain issuesQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - mfd.ru
Can Niagen Bioscience Inc be recession proofJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Does BNTX outperform in volatile marketsJuly 2025 Chart Watch & High Accuracy Swing Trade Signals - baoquankhu1.vn
Niagen Bioscience Sponsors Inaugural NAD for Health Conference - intellectia.ai
Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen - Business Wire
Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call? - simplywall.st
Niagen’s NAD+ Bet Is Paying Off, But The Price Is Steep - Finimize
Niagen Bioscience to Host Q4 and FY 2025 Earnings Call - Intellectia AI
Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 - Business Wire
Institutional Owners May Consider Drastic Measures as Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Recent US$69m Drop Adds to Long-term Losses - 富途牛牛
A Look At Niagen Bioscience (NAGE) Valuation As New Partner Launches And Clinical Data Gain Attention - Sahm
Assessing Niagen Bioscience (NAGE) Valuation As NAD+ IP And Upcoming Clinical Data Draw Renewed Attention - Yahoo Finance
Niagen Bioscience, Inc. (NAGE): A Bull Case Theory - Finviz
Niagen Bioscience Boosts TRU NIAGEN Sales on Amazon and Online - RS Web Solutions
How Investors Are Reacting To Niagen Bioscience (NAGE) Expanding TRU NIAGEN Distribution Through Amazon And E-Commerce - Yahoo Finance
Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Promising Upside with a 163.77% Potential - DirectorsTalk Interviews
Earnings Beat: Is now the right time to enter Niagen Bioscience Inc2025 Biggest Moves & Real-Time Buy Zone Alerts - baoquankhu1.vn
Aug PreEarnings: Can GPJA weather a recessionGlobal Markets & Entry Point Strategy Guides - baoquankhu1.vn
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-01-30 06:37:48 - baoquankhu1.vn
Niagen Bioscience (NASDAQ:NAGE) Shares Down 3.4%Here's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Shares Down 3.4% – Here’s What Happened - Defense World
Assessing Niagen Bioscience (NAGE) Valuation After New Truemed HSA And FSA Partnership - Sahm
Niagen Bioscience, Inc. (NAGE) Stock Analysis: Unveiling a 151% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Published on: 2026-01-20 17:04:22 - baoquankhu1.vn
Will Niagen Bioscience Inc outperform its industry peers2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Exit Recap: What is the Moat Score of Niagen Bioscience IncBond Market & Community Consensus Stock Picks - baoquankhu1.vn
Can Niagen Bioscience’s (NAGE) HSA Access Shift Redefine Its Direct-to-Consumer Growth Strategy? - Yahoo Finance
Revenue Check: Is now the right time to enter Niagen Bioscience IncTrade Exit Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
A Look At Niagen Bioscience (NAGE) Valuation After New HSA And FSA Purchasing Option For Tru Niagen - Sahm
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen By Investing.com - Investing.com Nigeria
NAGE: Niagen Bioscience advances NAD health solutions, expanding into IV, telehealth, and skincare - TradingView — Track All Markets
Niagen Bioscience (NAGE) Valuation In Focus As Investor Summit Appearance Nears - Yahoo Finance
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S. - morningsun.net
Niagen Bioscience now allows HSA/FSA payments for Tru Niagen - Investing.com
Is Niagen Bioscience (NAGE) Using Investor Summits To Recast Its Healthy Aging Strategy Narrative? - simplywall.st
Insider Buy: Whats the beta of Niagen Bioscience Inc stockEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Will Weakness in Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Is Niagen Bioscience Inc. stock resilient to inflationMarket Growth Report & Entry and Exit Point Strategies - Улправда
Niagen Bioscience, Inc. (NAGE) Stock Analysis: 140.85% Upside Potential Captures Investor Attention - DirectorsTalk Interviews
Published on: 2026-01-08 21:02:30 - Улправда
Will Niagen Bioscience Inc. stock benefit from sector rotationWeekly Profit Report & Fast Momentum Stock Entry Tips - ulpravda.ru
Will Niagen Bioscience Inc. stock deliver shareholder valueJuly 2025 Momentum & Consistent Return Strategy Ideas - ulpravda.ru
Why Niagen Bioscience Inc. stock attracts global investorsJuly 2025 Gainers & Smart Swing Trading Alerts - Улправда
Published on: 2026-01-09 00:19:58 - Улправда
Should I hold or sell Niagen Bioscience Inc. stock in 20252025 Bull vs Bear & Weekly High Potential Alerts - ulpravda.ru
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pamir Ozan | Chief Financial Officer |
Nov 14 '25 |
Buy |
6.85 |
2,220 |
15,210 |
2,220 |
| Fried Robert N | Chief Executive Officer |
Apr 09 '25 |
Option Exercise |
3.30 |
66,667 |
220,001 |
1,038,981 |
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):